phase III clinical study Dec 13, 2022 Amgen to Seek Blincyto Approval in MRD-Negative ALL Following Positive Phase III Results Premium Dec 8, 2022 Circulating Tumor Cell-Guided Treatment Improves Outcomes for Some Breast Cancer Patients Premium Dec 5, 2022 GlaxoSmithKline Eyes Regulatory Filing After Positive Phase III Jemperli Data in Endometrial Cancer Dec 5, 2022 Novartis to Seek Pluvicto Approval in Another Advanced PSMA-Positive Prostate Cancer Setting Nov 29, 2022 Alaunos Therapeutics Expecting $15.7M in Common Stock Offering Nov 29, 2022 Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication Nov 22, 2022 Kintara Therapeutics Hopes to Fill Treatment Gap in Glioblastoma With VAL-083 Premium Nov 17, 2022 Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators Nov 7, 2022 Telix Pharmaceuticals to Seek Marketing Approval in US, Abroad for TLX250-CDx Oct 25, 2022 Pluvicto Sales Ramp up, Kisqali Gains Continue in Q3 for Novartis Premium Oct 18, 2022 Gilead Sciences Nets Second-Line Yescarta Approval for Lymphoma Patients in Europe Oct 14, 2022 EMA's CHMP Recommends Novartis' Pluvicto for PSMA-Positive mCRPC Oct 4, 2022 Research Clarifies Immunotherapy, Targeted Treatment Order for BRAF-Mutant Melanoma Patients Premium Oct 3, 2022 Clovis Oncology to File sNDA for Rubraca in BRCA1/2-Mutant Prostate Cancer Sep 29, 2022 Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval Sep 20, 2022 Gradalis' Autologous Immunotherapy Shows Promise in Certain Ovarian Cancer Patients Premium Sep 19, 2022 EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma Sep 13, 2022 Combination Trials Point to New Potential Treatment Strategies in Breast Cancer Premium Sep 11, 2022 TIL Therapy Bests Yervoy in Head-to-Head Melanoma Trial; Will It Reach Patients Without Pharma? Premium Sep 10, 2022 Lilly's Verzenio Extends Five-Year Breast Cancer Survival, Adds to Debate Over Best CDK4/6 Inhibitor Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer